<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32276554</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>3-4</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>263</StartPage><EndPage>272</EndPage><MedlinePgn>263-272</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1746810</ELocationID><Abstract><AbstractText><b>Objective:</b> To determine the associations between plasma creatinine (PCr), plasma uric acid (PUA), and urinary oxidative stress (OS) biomarkers with the ALSFRS-R at baseline and survival in a large epidemiological cohort study (ALS COSMOS) with a well-phenotyped patient population (<i>N</i>&#x2009;=&#x2009;355).<b>Methods:</b> Fasting plasma and first void urine samples were obtained. PCr, PUA, urinary 8-oxo-deoxy guanosine (8-oxodG), and 15-F<sub>2t</sub>-isoprostane (IsoP) were analyzed at baseline, near the midpoint of follow-up, and at the final blood draw (before death or withdrawal from study). We estimated associations between these biomarkers and the ALSFRS-R at baseline and survival.<b>Results:</b> At baseline, PCr correlated with ALSFRS-R (Spearman <i>r</i>&#x2009;=&#x2009;0.30), percent (%) FVC (<i>r</i>&#x2009;=&#x2009;0.20), PUA (<i>r</i>&#x2009;=&#x2009;0.37), and 8-oxodG (<i>r</i> = -0.13, all <i>p</i>&#x2009;&lt;&#x2009;0.05). Baseline PCr significantly predicted survival (adjusted hazard ratio 0.28, <i>p</i>&#x2009;&lt;&#x2009;0.001). Time to death from baseline was shortest for those in the lowest two PCr quartiles relative to the highest two quartiles. PCr and ALSFRS-R values were significantly correlated at all three time points (baseline: <i>r</i>&#x2009;=&#x2009;0.29, midpoint: <i>r</i>&#x2009;=&#x2009;0.23, final: <i>r</i>&#x2009;=&#x2009;0.38, all <i>p</i>&#x2009;&lt;&#x2009;0.001). PCr and PUA significantly declined over time, whereas OS biomarkers significantly increased over time.<b>Conclusions:</b> To date, PCr predicted survival the best, compared to PUA, 8-oxodG, and IsoP. Although PCr represents the degree of muscle mass, it may also represent complex biochemical changes in ALS. Because the field has no reliable prognostic biomarkers, the importance of PCr warrants further investigation through clinical studies in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Eleanor and Lou Gehrig ALS Center, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garofalo</LastName><ForeName>Diana C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santella</LastName><ForeName>Regina M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorenson</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1725-9866</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes</LastName><ForeName>J Americo M</ForeName><Initials>JAM</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrews</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Data Coordinating Center (DCC), Mailman School of Public Health Biostatistics Department, Columbia University Irving Medical Center, New York State Psychiatric Institute &amp; Department of Psychiatry, Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hupf</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Eleanor and Lou Gehrig ALS Center, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilmore</LastName><ForeName>Madison</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Eleanor and Lou Gehrig ALS Center, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heitzman</LastName><ForeName>Daragh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Texas Neurology, PA, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Forbes Norris ALS Center, California Pacific Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barohn</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasarskis</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kentucky, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lomen-Hoerth</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mozaffar</LastName><ForeName>Tahseen</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nations</LastName><ForeName>Sharon P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurotherapeutics, University of Texas Southwestern, Dallas, TX, USA, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swenson</LastName><ForeName>Andrea J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Factor-Litvak</LastName><ForeName>Pam</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 ES009089</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES016348</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>268B43MJ25</RegistryNumber><NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>AYI8EX34EU</RegistryNumber><NameOfSubstance UI="D003404">Creatinine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003404" MajorTopicYN="N">Creatinine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014527" MajorTopicYN="N">Uric Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">creatinine</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">uric acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32276554</ArticleId><ArticleId IdType="mid">NIHMS1607811</ArticleId><ArticleId IdType="pmc">PMC7373369</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1746810</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LHSEGG, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry J, Chio A, Corcia P, Genge AL, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, , Silani V, Turner MR, Weber M, Brooks BR, Miller R, and Mitsumoto H. Airlie House ALS Clinical Trials Guidelines Group. Revised Airlie House Consensus Guidelines for Design and Implementation of ALS Clinical Trials. . Neurology. 2019;In Press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J. An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis. 1997;24(5):764&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">9142767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas-Blanco A, Machts J, Acosta-Cabronero J, Kaufmann J, Abdulla S, Kollewe K, et al. Structural and diffusion imaging versus clinical assessment to monitor amyotrophic lateral sclerosis. Neuroimage Clin. 2016;11:408&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4827722</ArticleId><ArticleId IdType="pubmed">27104135</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Geevasinga N, Yiannikas C, Howells J, Kiernan MC, Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. 2015;14(5):478&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25843898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, et al. ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Front Neurol. 2019;10:293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6446974</ArticleId><ArticleId IdType="pubmed">30972018</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(2):157&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D, Bejan-Angoulvant T, Patin F, Andres CR, Vourc&#x2019;h P, Corcia P, et al. Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">30961401</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Ulug AM, Pullman SL, Gooch CL, Chan S, Tang MX, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology. 2007;68(17):1402&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">17452585</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, et al. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(3&#x2013;4):192&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310702</ArticleId><ArticleId IdType="pubmed">24564738</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieves JW, Gennings C, Factor-Litvak P, Hupf J, Singleton J, Sharf V, et al. Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2016;73(12):1425&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5370581</ArticleId><ArticleId IdType="pubmed">27775751</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, et al. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology. 2016;86(9):813&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793785</ArticleId><ArticleId IdType="pubmed">26802094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9(3):177&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Graul RJ, Stanley RL. Specific gravity adjustment of urine analysis results. Am Ind Hyg Assoc J. 1982;43(11):863.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizopoulos D Joint Models for Longitudinal and Time-to-Event Data: With Applications in R Boca Raton: Chapman and Hall/CRC; 2012.</Citation></Reference><Reference><Citation>Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71(9):1134&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(1):37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16036424</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33(1):51&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25362243</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F, Corcia P, Madji Hounoum B, Veyrat-Durebex C, Respaud E, Piver E, et al. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. Eur J Neurol. 2015;22(10):1385&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">26095828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):406&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">25125035</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, van den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2018;89(2):156&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">10893433</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett AJ, Griggs RC, Moxley RT, 3rd. Skeletal muscle catabolism in amyotrophic lateral sclerosis and chronic spinal muscular atrophy. Neurology. 1982;32(5):550&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">7200211</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH. Is ALS a systemic disorder? Evidence from muscle mitochondria. Exp Neurol. 2006;198(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">16458887</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris FHD,EH, Sang K ALS Cachecia In: , editor. Amyotroph Lateral Sc. Baltimore: ; 1979. . ALS Cachecia In: Tsuabki TT,Y, editor. Amyotroph Lateral Sc. Baltimore: University Park Press; 1979. p. 17&#x2013;9.</Citation></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstrom H, Ingre C, Jungner I, Ye W, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017;81(5):718&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Beard JD, Umbach DM, Bellocco R, Keller J, Peters TL, et al. Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans. Am J Epidemiol. 2017;185(5):362&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860019</ArticleId><ArticleId IdType="pubmed">28158443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouteloup C, Desport JC, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, et al. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol. 2009;256(8):1236&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">19306035</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, Cajamarca SA, Hupf JC, et al. Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients. Mol Neurodegener. 2017;12(1):76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655870</ArticleId><ArticleId IdType="pubmed">29065921</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzo F, Mirra A, Carri MT. Oxidative stress and mitochondrial damage in the pathogenesis of ALS: New perspectives. Neurosci Lett. 2017;636:3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27150074</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009;285(1&#x2013;2):95&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19552925</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259(9):1923&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4441749</ArticleId><ArticleId IdType="pubmed">22323210</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SI, Baek S, Park JS, Piao L, Oh KW, Kim SH. Prognostic Role of Serum Levels of Uric Acid in Amyotrophic Lateral Sclerosis. J Clin Neurol. 2015;11(4):376&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596112</ArticleId><ArticleId IdType="pubmed">26424237</ArticleId></ArticleIdList></Reference><Reference><Citation>Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000;376(2):333&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10775420</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Camandola S, Malott KF, Edelhauser MA, Mattson MP. The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders. Curr Top Med Chem. 2015;15(21):2233&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5851449</ArticleId><ArticleId IdType="pubmed">26059354</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte AI, Santos MS, Oliveira CR, Rego AC. Insulin neuroprotection against oxidative stress in cortical neurons--involvement of uric acid and glutathione antioxidant defenses. Free Radic Biol Med. 2005;39(7):876&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">16140208</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Chen CP, Tseng CY, Eisenberg Y, Firestein BL. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia. 2007;55(5):463&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">17203476</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21(3):104&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6837462</ArticleId><ArticleId IdType="pubmed">26191780</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller FL, Song W, Jang YC, Liu Y, Sabia M, Richardson A, et al. Denervation-induced skeletal muscle atrophy is associated with increased mitochondrial ROS production. Am J Physiol Regul Integr Comp Physiol. 2007;293(3):R1159&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">17584954</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et al. Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. Can J Neurol Sci. 2017;44(1):90&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27774920</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88(24):2302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(10):e0164625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5061412</ArticleId><ArticleId IdType="pubmed">27732645</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90(1):e22&#x2013;e30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>